(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 November 2021 (11.11.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/224235 A1

(51) International Patent Classification:
A61K 31/495 (2006.01) *A61P 25/16* (2006.01)
A61P 25/00 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:
PCT/EP2021/061689

(22) International Filing Date:
04 May 2021 (04.05.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20305429.1 04 May 2020 (04.05.2020) EP

(71) Applicant: **BIOPROJET PHARMA** [FR/FR]; 9 rue Rameau, 75002 PARIS (FR).

(72) Inventors: **LECOMTE, Jeanne-Marie**; 30 rue des Francs-Bourgeois, 75003 PARIS (FR). **SCHWARTZ, Jean Charles**; 9 Villa Seurat, 75014 PARIS (FR). **BERREBI-BERTRAND, Isabelle**; 11 rue de Vergéal, 35740 PACE (FR). **KRIEF, Stéphane**; 6 cours d'Helsinki, 35200 RENNES (FR). **LIGNEAU, Xavier**; 4 Square du Vivier Louis, 35760 SAINT-GRÉGOIRE (FR). **LECOMTE, Isabelle**; 23 rue Melingue, 75019 PARIS (FR).

(74) Agent: **HABASQUE, Etienne** et al.; LAVOIX, 2, Place d'Estienne d'Orves, 75441 PARIS CEDEX 09 (FR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: USE OF DOPAMINE D3 PARTIAL AGONISTS FOR TREATING CENTRAL NERVOUS SYSTEM DISORDERS

(57) Abstract: The present invention provides for the use of D3 partial agonists for treating or inhibiting the restless leg syndrome (RLS), binge eating, essential tremor and neurodegenerative diseases, in particular D3 partial agonists/D2 antagonists.

WO 2021/224235 A1